Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Artivion's Stock on Promising AMDS Outlook and Financial Impact
Needham Reiterates Buy on Artivion, Maintains $30 Price Target
Artivion Is Maintained at Buy by Stifel
Artivion Analyst Ratings
Stifel Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $30
Stifel Maintains Artivion(AORT.US) With Buy Rating, Raises Target Price to $30
Needham Reiterates Buy on Artivion, Maintains $30 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Insulet (PODD) and Artivion (AORT)
Oppenheimer Reaffirms Their Buy Rating on Artivion (AORT)
Artivion Analyst Ratings
Oppenheimer Adjusts Artivion Price Target to $30 From $25, Maintains Outperform Rating
Artivion's Robust Financial Performance and Growth Prospects Justify Buy Rating
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $30
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $30
Lake Street Sticks to Their Buy Rating for Artivion (AORT)
Artivion Analyst Ratings
Lake Street Maintains Buy on Artivion, Raises Price Target to $30
Artivion's Strong Market Position and Revised Endospan Deal Justify a Buy Rating and Increased Price Target
Stifel: Maintaining the Artivion (AORT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $22.00 to $25.00.